Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers


Partagez l'article

Challenge: Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness.

Solution: This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of action in vitro and in vivo models of cancer metastasis, and by analyzing its pharmacokinetics and stability in biological fluids. The research team will also verify that TH1902 is functional in several types of metastatic cancers.

Expected Achievements /Impacts: Overall, the resulting data will support and better define future clinical trials in patients with sortilin-positive metastatic cancers and to further explore the potential combination of its compound with other therapeutic drugs. The identification of new treatment options for patients with overexpression of the sortilin receptor offers tremendous hope, particularly for tumors that are refractory to available anti-cancer treatments.

Principal Investigator :
Borhane Annabi
Co-Investigators : N/A
Project of
$1,590,000 over 2,5 years
Supported by CQDM through :
– Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE)
And by co-funding partners :
– Theratechnologies
– Quebec Breast Cancer Foundation
– Mitacs
Scroll to Top